1. Home
  2. MEIP vs HUSA Comparison

MEIP vs HUSA Comparison

Compare MEIP & HUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • HUSA
  • Stock Information
  • Founded
  • MEIP 2000
  • HUSA N/A
  • Country
  • MEIP United States
  • HUSA United States
  • Employees
  • MEIP N/A
  • HUSA N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • HUSA Oil & Gas Production
  • Sector
  • MEIP Health Care
  • HUSA Energy
  • Exchange
  • MEIP Nasdaq
  • HUSA Nasdaq
  • Market Cap
  • MEIP 17.1M
  • HUSA 16.8M
  • IPO Year
  • MEIP 2003
  • HUSA N/A
  • Fundamental
  • Price
  • MEIP $2.15
  • HUSA $0.73
  • Analyst Decision
  • MEIP Hold
  • HUSA
  • Analyst Count
  • MEIP 2
  • HUSA 0
  • Target Price
  • MEIP $7.00
  • HUSA N/A
  • AVG Volume (30 Days)
  • MEIP 8.3K
  • HUSA 400.1K
  • Earning Date
  • MEIP 05-08-2025
  • HUSA 05-14-2025
  • Dividend Yield
  • MEIP N/A
  • HUSA N/A
  • EPS Growth
  • MEIP N/A
  • HUSA N/A
  • EPS
  • MEIP N/A
  • HUSA N/A
  • Revenue
  • MEIP N/A
  • HUSA $560,180.00
  • Revenue This Year
  • MEIP N/A
  • HUSA N/A
  • Revenue Next Year
  • MEIP N/A
  • HUSA N/A
  • P/E Ratio
  • MEIP N/A
  • HUSA N/A
  • Revenue Growth
  • MEIP 33.76
  • HUSA N/A
  • 52 Week Low
  • MEIP $2.15
  • HUSA $0.72
  • 52 Week High
  • MEIP $4.11
  • HUSA $3.20
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 27.69
  • HUSA 27.93
  • Support Level
  • MEIP $2.28
  • HUSA $0.72
  • Resistance Level
  • MEIP $2.35
  • HUSA $1.49
  • Average True Range (ATR)
  • MEIP 0.07
  • HUSA 0.07
  • MACD
  • MEIP -0.00
  • HUSA -0.02
  • Stochastic Oscillator
  • MEIP 0.00
  • HUSA 9.33

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About HUSA Houston American Energy Corporation

Houston American Energy Corp is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. Its properties, and operations, are in the U.S. Permian Basin, the U.S. Gulf Coast region, particularly Louisiana, and the South American country of Colombia. Geographically, the company currently has operations in two geographical areas, the United States, from where it derives maximum revenue, and Colombia.

Share on Social Networks: